A practical radiosynthesis of a tritium-labelled fluorocombretastatin: A Practical Radiosynthesis of a Tritium-Labelled Fluoro Combretastatin

Zybrestat (combretastatin A-4 disodium diphosphate) is currently in clinical trials as an antivascular anticancer agent. A similar fluorinated agent has shown promise as an antivascular agent, and a radiolabelled version would enable further understanding of its biological activities. Herein is described the synthesis of a tritiated fluorinated analogue of Zybrestat. Copyright (c) 2012 John Wiley & Sons, Ltd.